Early insights from commercialization of gene therapies in Europe

Genes

Volumn 8, Issue 2, 2017, Pages

  Touchot, Nicolas ^a   Flume, Mathias ^b  

^a Strategy Consulting   (United Kingdom)

^b Kassenärztliche Vereinigung Westfalen Lippe Vorstand Ressort II   (Germany)

Author keywords

Commercialization; Gene therapies; Glybera; Imlygic; Market access; Payers; Reimbursement; Strimvelis

Indexed keywords

ALIPOGENE TIPARVOVEC; STRIMVELIS; TALIMOGENE LAHERPAREPVEC;

ADENOSINE DEAMINASE DEFICIENCY; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SCREENING; EUROPE; GENE THERAPY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; LONG TERM SURVIVAL; MELANOMA; NOTE; REIMBURSEMENT; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL GENE THERAPY;

EID: 85013297991     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes8020078     Document Type: Note

References (5)

1. Federal Joint Committee. Available online: http://www.english.g-ba.de/downloads/91-1028-146/Alipogene%20tiparvovec_ENG_2015-05-21.pdf (accessed on 22 December 2016).
2. HAS-Sante. Available online: http://www.has-sante.fr/portail/upload/docs/evamed/CT-14224_GLYBERA_PIC_INS_Avis3_CT14224.pdf (accessed on 22 December 2016).
3. National Institute of Clinical Excellence. Available online: https://www.nice.org.uk/guidance/indevelopment/gid-tag509 (accessed on 22 December 2016).
4. IQWiG. Available online: https://www.iqwig.de/en/press/press-releases/press-releases/talimogene-laherparepvec-in-melanoma-added-benefit-not-proven.7563.html (accessed on 22 December 2016).
5. NICE. Available online: https://www.nice.org.uk/Media/Default/About/what-we-do/Science%20policy% 20and%20research/Regenerative-medicine-study-march-2016.pdf (accessed on 22 January 2017)